This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / VistaGen Therapeutics Faces...
Regulatory securities lawsuit

VistaGen Therapeutics Faces Securities Lawsuit

Analysis based on 13 articles · First reported Jan 29, 2026 · Last updated Feb 17, 2026

Sentiment
-20
Attention
2
Articles
13
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted for VistaGen Therapeutics as the lawsuit creates uncertainty and potential financial liabilities. For the broader pharmaceutical industry, it highlights the importance of transparent clinical trial reporting.

Pharmaceuticals Legal Services
Event Summary

VistaGen Therapeutics is facing a securities fraud class action lawsuit filed by Bernstein Liebhard LLP on behalf of investors who purchased shares between April 1, 2024, and December 16, 2025. The lawsuit, filed in the United States===United States District Court for the Northern District of California, alleges that VistaGen Therapeutics and its senior officers made misrepresentations concerning the company's Phase 3 PALISADE-3 trial study of fasedienol, a candidate for social anxiety disorder. Investors have until March 16, 2026, to file papers to serve as lead plaintiff.

Key Actions
100 Bernstein Liebhard LLP filed a securities fraud class action lawsuit VistaGen Therapeutics
90 VistaGen Therapeutics made alleged misrepresentations concerning Phase 3 PALISADE-3 trial
Entities Involved
stock
VistaGen Therapeutics
VistaGen Therapeutics is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding its Phase 3 PALISADE-3 trial of fasedienol. This lawsuit could lead to significant financial penalties and reputational damage for the company.
Importance 100 Sentiment -70
priv
Bernstein Liebhard LLP
Bernstein Liebhard LLP is an investor rights law firm that initiated and is representing investors in the securities fraud class action lawsuit against VistaGen Therapeutics. The firm stands to gain financially if the lawsuit is successful.
Importance 80 Sentiment 50
govactor
United States===United States District Court for the Northern District of California
The United States===United States District Court for the Northern District of California is the venue where the securities fraud class action lawsuit against VistaGen Therapeutics was filed.
Importance 20 Sentiment 0
per
Peter Allocco
Peter Allocco is the Investor Relations Manager at Bernstein Liebhard LLP and serves as a contact point for investors interested in the VistaGen Therapeutics lawsuit.
Importance 10 Sentiment 0
Relationships
Bernstein Liebhard LLP related ↔ VistaGen Therapeutics
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.